Pharmacokinetics and PharmacoDynamics of GW685698 in Paedeatric Asthmatic Patients

ClinicalTrials.gov ID: NCT01332292

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT01332292. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:56 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-blind, Placebo-controlled, Two-way Crossover 14-day Study to Investigate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Repeat Dose Inhaled Fluticasone Furoate 100ug (Micrograms) in Children Aged 5-11 Years With Persistent Asthma

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study will investigate the effect of dosing with flutucasone furoate in asthmatic subjects aged 5-11 years of age. A randomized, two-way crossover, with placebo control, over a 14 day treatment period, it will investigate safety, tolerability, pharmacokinetics and serum cortisol levels.

Study identification

NCT ID: NCT01332292
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: GlaxoSmithKline; Industry
Enrollment: 27 participants

Conditions and interventions

Conditions

Asthma

Interventions

Fluticasone furoate Drug
Matching placebo Drug

Drug

Eligibility (public fields only)

Age range: 5 Years to 11 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: May 2010 (Type not available)
Primary completion: Jan 2011 (Actual)
Completion: Jan 2011 (Actual)
Last update posted: Mar 23, 2017

2010 – 2011

United States locations

U.S. sites: 5
U.S. states: 4
U.S. cities: 5

Facility	City	State	ZIP	Site status
GSK Investigational Site	Cypress	California	90630	—
GSK Investigational Site	Huntington Beach	California	92647	—
GSK Investigational Site	Denver	Colorado	80206	—
GSK Investigational Site	Normal	Illinois	61761	—
GSK Investigational Site	Medford	Oregon	97504	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT01332292, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Mar 23, 2017 · Synced Nov 15, 2026